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Study data were managed using REDCap electronic data capture tools hosted at University 
College London. REDCap (Research Electronic Data Capture) is a secure, web-based 
application designed to support data capture for research studies, providing: 1) an intuitive 
interface for validated data entry; 2) audit trails for tracking data manipulation and export 
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Abstract 
The burden of paediatric HCV infection across Europe is unknown, as are current policies 
regarding monitoring and treatment. This collaborative study aimed to collect aggregate data 
to characterise the population of ≤18-year olds with HCV infection in specialist follow up in 
a twelve-month period (2016) across the PENTAHep European consortium, and investigate 
current policies around monitoring and treatment. A cross-sectional, web-based survey was 
distributed in April 2017 to 50 paediatricians in 19 European countries, covering patients’ 
profile, and monitoring and treatment practices. Responses were received from 38/50 
clinicians collectively caring for 663 children with chronic HCV infection of whom three-
quarters were aged ≥6 years and 90% vertically-infected. HCV genotype 1 was the most 
common (n 380; 57.3%), followed by genotype 3, 4 and 2. Seventeen children (3%) with 
chronic HCV infection were diagnosed with cirrhosis and 6 were reported to have received 
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liver transplantation for HCV-related liver disease. The majority (n 425; 64.1%) of the 
European children with HCV infection remained treatment-naive in 2016. Age affected 
clinicians’ attitudes towards treatment; 94% reported being willing to use direct-acting 
antivirals, if available, in adolescents (aged ≥11 years), 78% in children aged 6-10 and 42% 
in those 3 to 5 years of age (Pearson correlation coefficient -0.98; p 0.0001). This survey 
provides the largest characterisation of the population of children in clinical follow-up for 
chronic HCV infection in Europe, alongside important contextual information on their 
management and treatment. Discussion is needed around strategies and criteria for use of 
direct-acting antivirals in these children. 
 
Keywords: epidemiology; vertical transmission; direct-acting antivirals; treatment; Europe 
 
Hepatitis C virus (HCV) infection is a major cause of liver-related morbidity and mortality 2-
5. According to latest estimates, 71 million people are living with HCV worldwide 2,3,6 of 
whom 2.1 million are children younger than 15 years 7. Major gaps exist in the current 
knowledge on the epidemiology of HCV infection in adults and children, including the true 
burden of infection and disease, and most HCV-infected people are unaware of their status 6. 
In the USA, less than 15% of HCV-infected children are thought to be diagnosed and a small 
fraction receives medical care 8. It is likely that the ascertainment rate of paediatric cases of 
HCV in Europe is as low as in USA although this topic has never been formally investigated. 
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Starting in 2015 with the approval of second-generation direct-acting antivirals (DAAs) 
active against HCV, the clinical and therapeutic approach to HCV infection in adults has 
changed substantially. With an efficacy approaching 100%, these new regimens raise the 
prospect of eliminating HCV on a population level. Indeed, the availability of DAAs was a 
driving force behind current ambitious World Health Organization targets for viral hepatitis, 
including the target to reduce new cases of chronic hepatitis B and C by 90% by 2030. 
 
Chronic HCV infection in children is considered a mild disease in general 9,10. Liver fibrosis 
and inflammation in children with chronic HCV infection is time-dependent and slow to 
progress 9-11 with only around 2% of vertically HCV-infected children developing advanced 
liver disease during childhood, although it is not possible to predict who will progress rapidly 
9-12. In general, although few children will experience end-stage liver disease during 
childhood, they will be at risk of cirrhosis and hepatocellular carcinoma in early adulthood 9-
11. Treatment options for children are currently limited. In 2017, both the Food and Drug 
Administration (FDA) and the European Medicines Agency (EMA) approved the use of 
sofosbuvir/ledipasvir (genotype 1, 4) and sofosbuvir in combination with ribavirin (genotype 
2,3) for treatment of adolescents (12-18 years of age) with chronic HCV infection. However, 
for children younger than 12 years there are no approved HCV treatment regimens and there 
are challenges with respect to availability of DAAs for adolescents across Europe.  
 
In the interferon (IFN)-era, its role in treatment of children with chronic HCV infection was 
controversial 13. The mild nature of HCV infection in children together with the low efficacy 
and the burdensome safety profile of IFN-based treatments have generally explained low use 
in children 14. With the availability of DAAs and very favourable safety and efficacy profiles 
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in adults, paediatric treatment of HCV can be reconsidered 4,15,16; however, in some countries 
barriers may remain around the costs of the new therapies and perceived lack of need for 
treatment in childhood.  
 
The burden of paediatric HCV infection across Europe is unknown, as are current policies 
around monitoring and treatment of paediatric HCV infection in a rapidly changing treatment 
context. The main aim of the present collaborative study was to collect aggregate data to 
characterise the population of children and adolescents (aged ≤18 years) with HCV infection 
in specialist follow up over a 12-month period (2016) across the PENTAHep European 
consortium, and to investigate current policies around monitoring and treatment. 
 
Materials and Methods 
PENTAHep and survey participants 
The PENTAHep Consortium, established in 2015, is a collaboration of partners (mainly 
clinical providers) from organizations across Europe, Egypt and the USA involved in 
research, development and clinical care in paediatric HCV infection. The aim of PENTAHep 
is to generate evidence to inform best practices for the care and treatment of children and 
adolescents living with HCV infection in the era of DAA. For this study, a survey was 
conducted within the PENTAHep network among European paediatricians selected because 
they had a special interest in paediatric hepatology and infectious diseases and have followed 
up children with chronic HCV infection for at least two years before the survey. Fifty 
paediatricians (31 hepatologists and 19 infectiologists) in 17 countries (Austria, Belgium, 
France, Germany, Greece, Hungary, Italy, Ireland, Netherland, Poland, Portugal, Romania, 
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Spain, Switzerland, Sweden, Turkey and UK) received an emailed invitation to complete the 
web-based survey (implemented using REDCap)1 in April 2017. Respondents did not receive 
any honorarium for completing the survey. Ethical approval was not required for this service 
evaluation study because individual patient data were not collected.  
 
Survey content and development 
The survey consisted of 20 items divided into two sections: patients’ profile; and monitoring 
and treatment practice (see Supporting information). Cross-sectional, aggregate data were 
collected on number of patients with chronic HCV infection in follow-up at each site in 2016 
by age group (0-<3; 3-5; 6-10; 11-18 years), sex, HCV genotype, mode of HCV transmission 
and co-infection with human immunodeficiency virus (HIV) and/or hepatitis B virus (HBV), 
and HCV treatment experience. Monitoring and treatment strategies were explored presenting 
specific case scenarios. 
The survey was piloted with two of the clinicians/respondents to assess clarity and validity. 
Modifications were made based on feedback and comments.  
 
Definitions 
Europe was divided in two major areas (Western European countries - WEC – and Central 
European countries – CEC – Figure 1) as previously reported 17. Chronic HCV infection was 
defined as the continued presence of HCV ribonucleic acid (RNA) in the blood six months or 
more after acquiring infection4. 
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Statistical analysis 
Standard descriptive statistics were used to describe response frequency. The χ2 test was used 
to compare categorical variables; a two-sided p<0.05 was considered to be statistically 
significant. The correlation between the willingness to use DAAs and the age of the patients 
was evaluated using the Pearson correlation coefficient. A Pearson's r value > ±0.8 in 
conjunction with a p-value of <0.05 in the significance test was considered to indicate a 
strong correlation. All analyses were conducted using MedCalc Statistical Software version 
17.6 (MedCalc Software bvba, Ostend, Belgium; http://www.medcalc.org; 2017). 
 
Results  
Completed survey responses were obtained from 38 (76%) of the 50 paediatricians invited to 
complete the survey from 35 hospitals. Data were obtained from 15/17 (88.3%) countries 
(Austria, Belgium, France, Germany, Greece, Hungary, Italy, Poland, Portugal, Romania, 
Spain, Sweden, Switzerland, Turkey and UK; Ireland and Netherlands were not included due 
to the lack of reply). These 38 paediatricians were collectively caring for 663 children with 
chronic HCV infection. 
 
Patient characteristics 
Characteristics of the children with chronic HCV cared for by the 38 survey respondents 
according to the European region of origin are shown in Table 1. Three-quarters of the 
children were aged 6 years or older. Vertical transmission was the main route of transmission 
of HCV infection, followed by nosocomial or unsafe blood product transfusion routes; there 
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were no reported cases with injecting drug use as the mode of transmission (Table 1). Six-
hundred and fifty-nine (99.4%) children were HCV mono-infected and 4 (0.6%) were co-
infected with HIV (0.3% [2/587] in WEC and 2.6% [2/76] in CEC; p=0.05). No child was co-
infected with HBV. HCV genotype 1 was the most common, followed by genotype 3, 4 and 2 
(Table 2). Zero HCV genotype 2 infections were reported in CEC compared with 5.8% in 
WEC. Genotype 3 infections were reported in 9.2% (7/76) and in 20.4% (120/587) of the 
children reported in CEC and WEC, respectively. HCV genotype 2 and 3 infections were 
more common in WEC when compared to CEC (p 0.001; Table 2). 
 
Seventeen children (3%) with chronic HCV infection were diagnosed with cirrhosis at the 
responding centres between 2014 and 2016 (2.5% [15/587] in WEC and 2.6% [2/76] in 
CEC¸p 1); 6 (0.9%) were reported to have received or be listed for liver transplantation for 
HCV-related liver disease.  
Almost two-thirds (425, 64.1%) of children were treatment-naïve. Of the 238 who were 
treatment-experienced, 161 (67.6%) were unsuccessfully treated with pegylated (PEG)-IFN 
and ribavirin before 2016 and 77 (32.4%) received treatment in 2016. Among these 77 treated 
in 2016, 35 (45.5%) received PEG-IFN and ribavirin and 42 (54.5%) received DAAs 
(specific regimens not available).  Almost two-thirds (425, 64.1%) of children were 
treatment-naïve. Of the 238 who were treatment-experienced, 161 (67.6%) were 
unsuccessfully treated with pegylated (PEG)-IFN and ribavirin before 2016 and 77 (32.4%) 
received treatment in 2016. Among these 77 treated in 2016, 35 (45.5%) received PEG-IFN 
and ribavirin and 42 (54.5%) received DAA (specific regimens not available). Data on the 
outcome of treatment for the latter group of patients was not available for the present survey 
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Monitoring and treatment practices scenarios 
Transient elastography (TE) was reported to be used routinely for non-invasive assessment of 
liver fibrosis by 28/38 (74%) of the respondents. Among the paediatricians surveyed, 29% 
and 34% reported that they would perform a liver biopsy in a six-year-old and in a 14-year-
old boy with raised alanine aminotransferase (ALT) level respectively, while 11% and 13% 
would do so if ALT level was normal (6-year-old: p 0.08; 14-year-old: p 0.03). Overall, 42% 
and 47% of respondents reported that they would use liver biopsy as a diagnostic tool in order 
to decide whether to treat or not in a six and a 14-year-old child respectively (Table 3).  
 
The survey was completed before 2017 FDA and EMA approval of the use of sofosbuvir and 
ledipasvir in adolescents aged 12-18 years. Clinicians were asked which age groups they 
would treat, if DAAs were licensed for paediatric use (a question which is no longer 
hypothetical for adolescents but remains so for younger age groups); 92% of the respondents 
reported that they would treat children aged 11-18 years, 74% that they would treat those 
aged 6-10 years and 39% that they would treat those younger than 6 years (Pearson 
correlation coefficient -0.99; p 0.0001; Table 4). 
 
Discussion  
In this survey of 38 clinicians collectively caring for 663 chronically HCV-infected ≤18-year-
old patients across 15 European countries, we found that the majority of children in follow-up 
for HCV were treatment naïve based on 2016 data. The only drugs approved by the EMA for 
use in children at that time were PEG-IFN and ribavirin, a combination with high 
effectiveness (sustained virological response (SVR) around 90%) in children with HCV 
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genotype 2 or 3 infection, but rather low for genotype 1 and 4 (SVR approximately 50%)15,18; 
furthermore, adverse effects with PEG-IFN and RBV can be severe, requiring treatment 
discontinuation or dose modification, and sometimes persisting after the end of treatment 18-
21. The low efficacy and the burdensome safety profile of PEG-IFN and RBV was likely a 
factor contributing to the large number of treatment naïve HCV-infected children in follow-
up at participating centres at the time of the survey. Furthermore, given the overall mild 
course of HCV-related liver disease progression in childhood and the availability of DAAs 
for paediatric use on the horizon, it is likely that “warehousing” of paediatric patients was 
taking place in which treatment is delayed for well children, until more efficacious and less 
toxic regimens are licensed. 
 
In addition, our results indicate that other factors such as the age of the patient and the stage 
of liver disease may be important to the decision to treat. As part of the survey, paediatricians 
were asked about their willingness to use DAA therapies, well known to be highly effective 
and safe in adults and, according to the few data available, also in children 22-28. Ninety-three 
percent of the paediatricians surveyed reported willingness to use DAA if available in 
adolescents (aged 11 years or older), but fewer (74%) in children aged 6-10 and only 39% in 
those 3 to 5 years of age. Beside the efficacy of the treatment, the child’s age, therefore, is 
felt as important in the decision-making process about whether to treat HCV infection in 
children, as has been observed in HIV co-infected children 29. Overall, anti-HCV treatments 
are generally considered inappropriate for children younger than three years. Around 20% of 
the children who acquire HCV infection vertically can present spontaneous clearance in the 
first 30 months of life 30,31 and so three years is usually considered the threshold age to 
confirm the chronicity of vertically acquired HCV infection. Fibrosis development in children 
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with chronic HCV infection, although unpredictable, is dependent on different factors;  these 
include the aetiology of the infection (e.g. transfusion-transmitted HCV infection)32, the 
presence of co-morbidities (e.g. HIV co-infection)33 and the length and duration of the 
infection and therefore, especially for those vertically infected, on the age of the child 9-12. 
The association between increasing age of the child and the respondent’s willingness to use 
DAA here is probably dependent on the overall low risk of advanced liver disease in 
childhood. Around 50% of the paediatricians reported being willing to perform a liver biopsy 
in children aged 6 or 14 years to decide whether to start treatment or not, confirming the 
impact of disease severity in the treatment decision. As a further possible factor, we can 
speculate that the absence of data on the efficacy and safety of DAA in children younger than 
6 years could have influenced the response of paediatricians here. It is matter of debate and 
beyond the scope of this study, whether treatment should be deferred in young children until 
safe and effective DAA therapies are licensed. The possible benefits of an early treatment and 
cure not only include prevention of HCV-related disease (hepatic and extra-hepatic) but also 
the opportunity for the child to grow up free of potential stigma and psychological 
consequences of a chronic transmissible disease; other benefits may include reducing risk of 
future horizontal and vertical transmission, and reduced burden on families and health care 
providers. The pros of treatment should be balanced against cons including, for DAA, the 
cost of the therapy 34. 
 
The findings from this survey indicate that vertical transmission is the main route of 
transmission of HCV infection in the contemporary population of children with chronic HCV 
in clinical care in Europe. Injecting drug use was not reported among the routes of HCV 
acquisition in the present cohort of European children and adolescents. Recently, an increase 
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in cases of HCV infection among adolescents and young adults was described in the United 
States35. Focused studies and interventions are needed for young injecting drug users to 
engage them and provide access to comprehensive health services that include HCV testing 
and linkage to care. Knowledge of risk factors for HCV infection is crucial in resource 
allocation for prevention measures. In the DAA era this is particularly significant. The 
systematic screening of women of child-bearing age and/or during pregnancy for HCV is a 
possible route for expanding testing, case identification and treatment. Treatment of women 
with chronic HCV before pregnancy is one strategy to prevent vertical transmission, although 
preliminary work is ongoing to investigate use of DAAs in pregnancy (ClinicalTrials.gov 
identifier NCT02683005). Recent studies from the United States reported transmission of 
hepatitis C in adolescents through injecting drug use 35. A similar trend could not be 
confirmed in European children of the present cohort although linkage to care could be 
delayed and we cannot completely exclude this route of transmission. However, 3% of the 
children were reported as having acquired HCV infection nosocomially or through unsafe 
blood product transfusions. The present survey was designed to provide aggregate data, 
individual patient data were not collected on age or country of origin (or country where the 
infection was likely acquired). Since the introduction of universal screening of blood 
products for HCV was implemented in 1992, blood transfusions are no longer associated with 
HCV transmission in Western and Central Europe36. 
 
HCV genotype 1 was the most common genotype, followed by genotype 3. Genotypes 2 and 
3 were more common in WEC as compared to CEC as already demonstrated in previous 
studies 17. The epidemic of HCV infection in Europe is continuously evolving and 
epidemiological data have changed during the last 15 years. Genotype distribution is 
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associated with the mode of transmission, with subtypes 1a, 3a and 4 being mostly 
intravenous drug use (IDU) related and genotypes 1b and 2 associated with blood transfusion 
and unsafe medical procedures 36. The result of the public health drive in the 1990s towards 
reducing the risk of transfusion related HCV infection and the improvement of healthcare 
conditions has resulted in IDU becoming the main risk factor for HCV transmission in 
adults36. This shift has switched the HCV genotype distribution among young adults from 1b 
and 2 to 1a, 3a and 436. This study confirms the same genotype distribution of vertically 
acquired infections in children in Western and Central Europe. 
 
The present survey provides an estimate of the prevalence of HCV-related advanced liver 
disease in the study population, with cirrhosis reported in 3% and liver transplantation in 1%. 
This is consistent with previous prospective studies that estimated that around 5% of the 
children with vertically-acquired HCV infection progress to cirrhosis or bridging fibrosis 
during childhood 9,10,32. 
 
This survey also provides insights around common approaches to monitoring of liver disease 
progression in HCV-infected children. In the IFN-era, liver biopsy was generally indicated in 
children infected by HCV genotype 1 or 4, where PEG-IFN plus RBV treatment yields no 
more than 50% success, to justify expectant management if fibrosis was mild37. Around 50% 
of the paediatricians reported to be willing to perform a liver biopsy to assist their decision-
making for treatment, and more in the scenario of raised ALT. In adults, liver biopsy, the 
reference method for grading the necroinflammatory activity and staging of fibrosis, has now 
been replaced by non-invasive methods and TE 16,38. Nearly three-quarters of the respondent 
routinely use TE for non-invasive assessment of liver fibrosis in children. The diagnostic 
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performances of TE for staging fibrosis have been systematically and prospectively evaluated 
in large cohorts of HCV infected adults, with the clinical, anthropometric, biochemical, and 
histological features which might affect liver stiffness measurement identified. However, the 
use of TE in children with chronic viral hepatitis has been poorly evaluated and validated, 
with only five studies including 140 children to date 39-43. The results of TE should therefore 
be evaluated with extreme caution especially in very young children, and the confounding 
influences on test results of factors including probe choice, sedation, or food intake need to 
be considered when interpreting results and further evaluated. The high feasibility, 
acceptability and the non-invasive nature of TE could account for the wide use of TE found 
in the present study. 
 
This PENTAHep survey provides the largest ever characterisation of the population of 
children in clinical follow-up for chronic HCV infection in Western and Central Europe, 
alongside important contextual information on their management and treatment. Inclusion of 
respondents from 15 countries supports generalisability of findings in the region. However, as 
this was a cross-sectional survey, we are unable to assess changes in monitoring and 
treatment practices over time, or trends in patient characteristics. Since survey responses 
related only to children with chronic HCV infection who were in active medical follow-up in 
2016, we cannot make conclusions about the proportion undiagnosed, or previously 
successfully treated and discharged. Furthermore, we limited the number of questions on the 
patients’ clinical profile to maximize survey participation and completion. The absence of 
specific questions on the quality of life and extrahepatic manifestations among other co-
morbidities that could have affected the decision of paediatricians to prioritize treatment in 
children even in the era before DAA, are therefore limitations of the present study. 
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In conclusion, the preliminary insights into the current (2016) epidemiology of hepatitis C in 
children in Western and Central Europe provided by the survey will inform future research. 
Most HCV-infected children in active follow-up had acquired the infection vertically and had 
not been treated with IFN-based therapies. Screening for HCV in women of childbearing age 
should be evaluated and considered in the DAA era as a possible cost-effective measure 
bringing the “double dividend” of curing the woman and preventing vertical transmission. TE 
is widely used among European paediatricians although its diagnostic performance in 
children with chronic HCV infection should be carefully evaluated. DAA therapies are a 
promising opportunity for children with HCV with very positive attitudes to this treatment 
shown here among paediatricians caring for these children in Europe. As therapies become 
licensed for paediatric use, there is a need to generate evidence on their use in children and 
adolescents, including real-world safety, effectiveness and acceptability, in order to inform 
treatment and follow-up strategies. 
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Figure legend 
Figure 1. Survey responses were obtained from 38 paediatricians from 35 hospitals, from 15 
European countries; Europe was divided in two major areas (Western European countries – 
and Central European countries – CEC) as previously reported.17 
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Table 1. Characteristics of 663 children aged ≤18 years with chronic HCV infection in 
clinical follow-up in 2016 at 36 European centres 
 
 Total Western European 
Countries (n 587) 
Central European 
Countries (n 76) 
Age (years) n (%)   
0-3 68 
(10.3) 
47 (8) 21 (27.6)* 
4-5 82 
(12.4) 
68 (11.6) 14 (18.4) 
6-10 178 
(26.8) 
154 (26.2) 24 (31.5) 
11-18 335 
(50.5) 
318 (54.1) 17 (22.3)§ 
Gender    
Male 319 
(48.1) 
287 (48.8) 32 (42.1) 
Route of HCV transmission    
Vertical 595 
(89.8) 
531 (90.4) 64 (84.2) 
Nosocomial/unsafe blood 
product transfusions 
22 (3.3) 15 (2.5) 7 (9.2)^ 
Unknown 46 (6.9) 39 (6.6) 5 (6.5) 
 
Note: Central European Countries (CEC) vs Western European Countries (WEC) *§p 0.0001; 
^ p 0.008 
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Table 3. Liver biopsy scenarios: proportion of the 38 respondents that would perform a liver 
biopsy in children with chronic hepatitis C virus infection by age and situation 
 
   
 6-year-old patient 14-year-old patient 
Persistently normal ALT 4 (11%) 5 (13%) 
Persistently raised ALT 11 (29%) 13 (34%) 
To decide whether to treat or not 16 (42%) 18 (47%) 
 
Note: ALT, alanine aminotransferase 
 
 
Table 4. Attitudes of the 38 paediatricians towards use of direct-acting antivirals in children, 
if licensed for paediatric use  
 
If DAAs were available for paediatric use now, would you treat children aged: 
 Yes No Maybe 
3-5 years 15 (39%) 14 (37%) 9 (24%) 
6-10 years 28 (74%) 8 (21%) 2 (5%) 
11-18 years† 35 (93%) 3 (8%) 0 (0%) 
 
Note: DAAs, direct-acting antivirals; Pearson correlation coefficient -0.99; p 0.0001; †survey 
conducted in 2016, prior to FDA and EMA licensing of sofosbuvir and ledipasvir for 
adolescents aged 12-18 years 
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